Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 659,984 | 747,888 | 662,972 | 528,216 | 503,528 |
| Receivables | 13,585 | 24,649 | 21,910 | 21,606 | 46,124 |
| Other current assets | 24,246 | 28,566 | 29,223 | 37,338 | 32,023 |
| TOTAL | $709,557 | $812,845 | $714,105 | $587,160 | $584,145 |
| Non-Current Assets | |||||
| PPE Net | 95,811 | 103,931 | 111,706 | 120,038 | 126,834 |
| Intangibles | 454,243 | 472,061 | 484,386 | 505,589 | 493,902 |
| Other Non-Current Assets | 79,911 | 85,293 | 89,329 | 89,568 | 100,353 |
| TOTAL | $629,965 | $661,285 | $685,421 | $715,195 | $721,089 |
| Total Assets | $1,339,522 | $1,474,130 | $1,399,526 | $1,302,355 | $1,305,234 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 20,348 | 18,118 | 13,935 | 19,314 | 25,086 |
| Accrued Expenses | 54,205 | 70,230 | 73,360 | 84,538 | 56,804 |
| Other current liabilities | 32,794 | 37,605 | 47,364 | 39,690 | 39,651 |
| TOTAL | $129,699 | $147,707 | $155,103 | $164,026 | $141,981 |
| Non-Current Liabilities | |||||
| Long Term Debt | 7,181 | 9,564 | 11,902 | 14,196 | 16,446 |
| Other Non-Current Liabilities | 159,590 | 162,739 | 162,261 | 181,203 | 190,423 |
| TOTAL | $185,054 | $195,558 | $197,475 | $219,183 | $229,306 |
| Total Liabilities | $314,753 | $343,265 | $352,578 | $383,209 | $371,287 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 529,905 | 527,398 | 520,643 | 434,152 | 406,495 |
| Common Shares | 5 | 5 | 5 | 4 | 4 |
| Retained earnings | -2,193,506 | -2,076,002 | -1,967,879 | -1,805,589 | -1,633,694 |
| Other shareholders' equity | 26,662 | 36,717 | 34,093 | 43,620 | 14,145 |
| TOTAL | $1,024,769 | $1,130,865 | $1,046,948 | $919,146 | $933,947 |
| Total Liabilities And Equity | $1,339,522 | $1,474,130 | $1,399,526 | $1,302,355 | $1,305,234 |